Thus, based on our data presented here, on our previously published data that increased serum CCL18 correlates with decreased survival time in adenocarcinoma of the lung [22] and on the observation by Chen et al. demonstrating that CCL18 promotes metastasis in breast cancer [5] we hypothesized that CCL18 may be one of the key factors driving EMT in the tumor environment. The gene discussed is CCL18; the disease is breast carcinoma.